Table 2.
Preoperative clinical risk factors for 5-year survival in patients with HCC.
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
|
Age, >60 years vs. ≤60 years |
1.777 (0.959–3.291) |
0.068 |
1.693 (0.849–3.376) |
0.135 |
|
Sex, female vs. male |
1.132 (0.545–2.351) |
0.740 | ||
|
HBsAg/HCV-ab status, positive vs. negative |
0.874 (0.413–1.848) |
0.724 | ||
|
Cirrhosis, present vs. absent |
1.030 (0.525–2.022) |
0.932 | ||
|
Preoperative AFP level, >7 ng/mL vs. ≤7 ng/mL |
3.696 (2.017–6.773) |
<0.001* |
3.789 (1.986–7.231) |
<0.001* |
|
Preoperative ALT level, >40 U/L vs. ≤40 U/L |
1.002 (0.541–1.858) |
0.994 | ||
|
Preoperative AST level, >45 U/L vs. ≤45 U/L |
2.599 (1.344–5.026) |
0.005* |
2.692 (1.300–5.573) |
0.008* |
|
Preoperative TB level, >20 μmol/L vs. ≤20 μmol/L |
0.740 (0.350–1.565) |
0.430 | ||
|
Preoperative DB level, >6 μmol/L vs. ≤6 μmol/L |
1.563 (0.839–2.911) |
0.159 | ||
|
Preoperative ALB level, <35 g/L vs. ≥35 g/L |
2.473 (0.749–8.166) |
0.137 | ||
|
Preoperative PLT, <100 × 109/L vs. ≥100 × 109/L |
1.110 (0.551–2.238) |
0.770 | ||
|
Preoperative PT, >14 s vs. ≤14 s |
1.316 (0.506–3.423) |
0.574 | ||
|
Preoperative INR, >1.5 vs. ≤1.5 |
1.648 (0.685–3.963) |
0.264 | ||
|
Preoperative CP class, B vs. A |
0.932 (0.057–15.110) |
0.961 | ||
|
MRI-reported tumour number, >3 vs. ≤3 |
4.087 (1.117–14.957) |
0.033* |
1.555 (0.218–11.078) |
0.659 |
|
MRI-reported tumour size, >2 cm vs. ≤2 cm |
2.597 (1.154–5.847) |
0.021* |
1.959 (0.810–4.739) |
0.136 |
|
BCLC stage, B vs. 0/A |
3.611 (1.384–9.425) |
0.009* |
2.933 (0.665–12.938) |
0.155 |
AFP alpha-fetoprotein, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, CP Child–Pugh, DB direct bilirubin, HBsAg hepatitis B surface antigen, HCC hepatocellular carcinoma, HCV-ab hepatitis C Virus antibody, INR international normalised ratio, PLT platelet count, PT prothrombin time, TB total bilirubin, MRI magnetic resonance imaging, OR odds ratio, vs. versus
*P-value < 0.05